Promising heterometallic compounds as anticancer agents: Recent studies in vivo

Heterometallic ruthenium–osmium complexes: dual photodynamic and photothermal therapy for melanoma and drug-resistant lung tumourin vivo

“…During irradiation, the tumours in group IV showed a significant flattening and softening, with a slight increase in volume. Within 9 days (day [10][11][12][13][14][15][16][17][18][19], the tumour further flattened and expanded, showing an enlarged diameter and lowered height (Fig. 4b).…”

“…Heterometallic anticancer agents have shown diverse activities in chemotherapy, PACT, and theragnostic reagents. [14][15][16][17][18] Some cases of PDT-active Ru-Pt complexes have been reported, [19][20][21] whereas no heterometallic compound has demonstrated dual PDT/PTT antitumour activity so far. In-depth research on the phototherapeutic mechanism and regularity of the Ru-Os complexes will undoubtedly attract the attention of researchers in this field to heterometallic complexes.…”

Modulating the Chemical Reactivity of Gold Complexes in Living Systems: From Concept to Biomedical Applications

“…Within its working condition for rheumatoid arthritis, the off-target toxicity is often less severe, related to gastrointestinal diarrhea, skin rashes, and eye-related events. For other synthesized gold complexes, the in vivo efficacy and toxicity have been well-documented in other reviews. ,− …”

“…This Account discusses the concept of modulating the chemical reactivity of gold in living systems and highlights several examples developed in our group with such strategies for biomedical applications. It has been noted that recently several excellent reviews related to gold-based anticancer complexes with emphasizes on mechanism and specific ligands have been described elsewhere. − …”

A hydrolytically stable oxo-rhenium(v) antitumor agent for synergistic combination therapy with cisplatin: from synthesis and mechanistic studies to toxicity assessment in zebrafish

“…[5][6][7][8] These shortcomings have prompted researchers and clinicians to search for more effective strategies. 9 Extensive investigations on the antitumor potential of non-Pt metal complexes of ruthenium (Ru), [10][11][12] iridium (Ir), 13,14 titanium (Ti), 15 gold (Au) [16][17][18] etc., with distinct mechanisms of action than DNA-targeting Pt drugs, have led to the identification of several promising candidates which are in preclinical or advanced clinical trials. 19,20 Alternatively, combination therapy comprising a Pt drug and other drugs with a distinct mechanism of action (e.g.…”